KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Cost of Revenue: 2020-2024

Historic Cost of Revenue for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2024 value amounting to $68.6 million.

  • Esperion Therapeutics' Cost of Revenue rose 138.86% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.0 million, marking a year-over-year increase of 133.36%. This contributed to the annual value of $68.6 million for FY2024, which is 58.55% up from last year.
  • Per Esperion Therapeutics' latest filing, its Cost of Revenue stood at $68.6 million for FY2024, which was up 58.55% from $43.3 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Cost of Revenue peaked at $68.6 million during FY2024, and registered a low of $2.4 million during FY2020.
  • In the last 3 years, Esperion Therapeutics' Cost of Revenue had a median value of $43.3 million in 2023 and averaged $46.3 million.
  • Data for Esperion Therapeutics' Cost of Revenue shows a peak YoY soared of 494.36% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Cost of Revenue stood at $2.4 million in 2020, then surged by 494.36% to $14.2 million in 2021, then surged by 89.68% to $27.0 million in 2022, then spiked by 60.44% to $43.3 million in 2023, then soared by 58.55% to $68.6 million in 2024.